… targeting DNA damage response (DDR) mechanisms in cancer cells. Lynparza is currently approved by regulatory health authorities in the EU for use as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed …
Category: Myriad Pharmaceuticals
Myriad’s Prolaris Test Significantly Improves the Risk…
Myriad Genetics, Inc. , a global leader in personalized medicine, today announced new data demonstrating the utility of the ProlarisA test to more accurately classify mortality risk and guide the management of newly diagnosed men with prostate cancer. The data are being presented at the 2017 Genitourinary Cancers Symposium meeting in Orlando, Fla.